Generics Archives

Speakers at GPhA Fall Technical Workshop Warn that Firms Best Understand GDUFA Review Penalties

By Bob Pollock Oct 28, 2013 FDA Generics Regulatory Affairs

Speaking at the Pre-Meeting Project Manager Workshop, OGD staff reminded participants of the fact that in year 1 and 2 of GDUFA, there are no real metrics, and reviewed the GDUFA goals for years 3-5 of the five year program. Along with this reminder, OGD GDUFA Implementation Team Member Christina Kirby noted that all amendment goals are incremental, meaning that pre-FDA Action Amendments results in an adjustment of goal date and post-FDA Action Letter submissions sets a new goal date.

Oct

III to II – And So the Schedule Goes for Hydrocodone Combo Products

By Bob Pollock Oct 25, 2013 Compliance FDA Generics Regulatory Affairs

On October 24, 2013 the FDA announced its intent to recommend to the Drug Enforcement Administration (DEA) that Hydrocodone-containing combination products be rescheduled into the more restrictive Schedule II. Such a move will make it more difficult for patients to obtain the products, as well as for healthcare practitioners to prescribe these products.

Oct

You Can Huff and You Can Puff…but Not On These After December 31, 2013!

By Bob Pollock Oct 24, 2013 Compliance FDA Generics Regulatory Affairs

Not that it is a big surprise to current users (at least we hope not), but the FDA announced on October 23, 2013 that they were completing the phase-out of all medical inhalation products containing chlorofluorocarbons (CFCs) by December 31, 2013.

Oct

Is There Snake Oil in Them Thar Pills?

By Bob Pollock Oct 23, 2013 Compliance FDA Generics Regulatory Affairs

In a recent enforcement action against a dietary supplement manufacturer James G. Cole Inc. (here), the FDA is seeking a Permanent Injunction based on repeated violations of cGMPs and distribution of unapproved drugs. This type of “health fraud” dates back to the days of the traveling medicine men in their covered wagons selling dangerous concoctions of different herbs and drugs and making all kinds of wild health claims for products like Doctor Feel Good Elixir.

Oct

OTC Inhaled Steroid (Glucocorticoid) – Something I Never Thought Would Happen!

By Bob Pollock Oct 15, 2013 Compliance FDA Generics Regulatory Affairs

On October 11, 2013, the FDA made history by approving Nasacort Allergy 24H, an over-the-counter (OTC) version of the Rx Nasacort AQ (triamcinolone acetonide), a nasally inhaled glucocorticoid for allergy relief.

Oct

Back in the Headlines – FDA Updates Bioequivalence of Bupropion Extended-Release 300mg Tablets

By Bob Pollock Oct 11, 2013 FDA Generics Regulatory Affairs

On October 3, 2012, the FDA announced its finding that the Impax Bupropion Extended-Release Tablets, 300mg, distributed by Teva, was found to be bio-inequivalent to the reference listed drug (RLD) Welbutrin XL 300 mg Tablets. The firms withdrew their product from the market.
A little over a year later, on October 10, 2013, FDA announced the results of the bioequivalence studies required by four additional companies, Actavis, Mylan, Par Pharmaceuticals, and Watson conducted to confirm a finding of bioequivalence of their approved 300 mg Bupropion Extended-Release Tablets. The studies submitted by Actavis, Mylan, and Par Pharmaceuticals confirmed that their products are bioequivalent to Welbutrin XL 300 mg Tablets. However, the study performed by Watson failed to confirm bioequivalence to the RLD, and the firm has agreed to voluntarily withdraw its product from the distribution chain

Oct

FDA Shutdown Leads to Congress Pitching an Industry Shutout

By Bob Pollock Oct 08, 2013 FDA Generics Regulatory Affairs

The Government shutdown is on everyone’s minds, but, as always, things happen that many of us in the general public don’t think of right off the bat to keep the title’s metaphor going. The shutout comes for any fee-paying application, supplement, device or other FDA regulated product that industry attempted to submit to FDA on or after October 1, 2013.

Oct

Time to Tighten Your Belts and Pay Attention to Quality

By Bob Pollock Oct 07, 2013 FDA Generics Regulatory Affairs

This is not the first time that the Office of Generic Drugs (OGD) has issued a guidance document that requires firms to assure that they have essential information in their original abbreviated new drug applications to permit a substantive scientific review. Remember prior to the 1992 Hatch-Waxman final rule when an ANDA could be submitted […]

Oct

Is Part 11 Dead? Part 1 of a series– Electronic Records

By Bob Pollock Oct 07, 2013 Compliance FDA Generics Validation

Hardly! But Part 11 (21 CFR Part 11), which applies to records in electronic form and the use of electronic signatures required by predicate rule (i.e., those records required to be signed by GMP regulations), has been scrutinized and discussed among regulators and the industry over the years, and the industry is still waiting on […]

Oct

The MaPP to Nowhere!

By Bob Pollock Oct 06, 2013 FDA Generics Regulatory Affairs

For those of you who have not yet read MaPP 5200.3 (here). Responding to Industry Inquiries with Respect to Abbreviated New Drug Application in the Office of Generic Drugs, you better have your CEOs take a Valium prior to your reporting its contents. In a nutshell, it says you can call us – but only the […]

Prev 1 … 137 138 139 … 141 Next

Generics